Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study

Atherosclerosis

Volumn 217, Issue 1, 2011, Pages 165-170

  Noguchi, Tohru ^a   Kobayashi, Junji ^a   Yagi, Kunimasa ^b   Nohara, Atsushi ^a   Yamaaki, Naoto ^b   Sugihara, Masako ^b   Ito, Naoko ^b   Oka, Rie ^c   Kawashiri, Masa aki ^b   Tada, Hayato ^b   Takata, Mutsuko ^b   Inazu, Akihiro ^b   Yamagishi, Masakazu ^b   Mabuchi, Hiroshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b Graduate School of Natural Science and Technology   (Japan)

^c Department of Internal Medicine   (Japan)

Author keywords

Adiponectin; Bezafibrate; Diabetes; Dyslipidemia; Fenofibrate; PCSK9; Peroxisome proliferator activated receptor (PPAR)

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ADIPOCYTOKINE; ADIPONECTIN; APOLIPOPROTEIN B; BEZAFIBRATE; CHOLESTEROL; FENOFIBRATE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KEXIN; LEPTIN; SUBTILISIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINALYSIS;

ADIPOKINES; ADIPONECTIN; ADULT; AGED; BEZAFIBRATE; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, HDL; CROSS-OVER STUDIES; DEOXYGUANOSINE; DIABETES MELLITUS, TYPE 2; FEMALE; FENOFIBRATE; GLUCOSE TOLERANCE TEST; HUMANS; LEPTIN; MALE; MIDDLE AGED; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; TIME FACTORS; TRIGLYCERIDES;

EID: 79960239872     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.02.012     Document Type: Article

References (52)

1. Zhang D.W., Lagace T.A., Garuti R., et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007, 282:18602-18612.
2. Qian Y.W., Schmidt R.J., Zhang Y., et al. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res 2007, 48:1488-1498.
3. Lagace T.A., Curtis D.E., Garuti R., et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006, 116:2995-3005.
4. Rashid S., Curtis D.E., Garuti R., et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A 2005, 102:5374-5379.
5. Dubuc G., Chamberland A., Wassef H., et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004, 24:1454-1459.
6. Dong B., Wu M., Li H., et al. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res 2010, 51:1486-1495.
7. Careskey H.E., Davis R.A., Alborn W.E., Troutt J.S., Cao G., Konrad R.J. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 2008, 49:394-398.
8. Mayne J., Dewpura T., Raymond A., et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipid Health Dis 2008, 7:22.
9. Kourimate S., Le May C., Langhi C., et al. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. J Biol Chem 2008, 283:9666-9673.
10. Troutt J.S., Alborn W.E., Cao G., Konrad R.J. Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. J Lipid Res 2010, 51:345-351.
11. Costet P., Hoffmann M.M., Cariou B., Guyomarc'h Delasalle B., Konrad T., Winkler K. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis 2010, 212:246-251.
12. Willson T.M., Brown P.J., Sternbach D.D., Henke B.R. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000, 43:527-550.
13. Okazaki M., Sasamoto K., Muramatsu T., Hosaki S. Evaluation of precipitation and direct methods for HDL-cholesterol assay by HPLC. Clin Chem 1997, 43:1885-1890.
14. Labeur C., Shepherd J., Rosseneu M. Immunological assays of apolipoproteins in plasma: methods and instrumentation. Clin Chem 1990, 36:591-597.
15. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
16. Hosoda K., Masuzaki H., Ogawa Y., et al. Development of radioimmunoassay for human leptin. Biochem Biophys Res Commun 1996, 221:234-239.
17. Dubuc G., Tremblay M., Pare G., et al. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res 2010, 51:140-149.
18. Cariou B., Le Bras M., Langhi C., et al. Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients. Atherosclerosis 2010, 211:700-702.
19. Lakoski S.G., Lagace T.A., Cohen J.C., Horton J.D., Hobbs H.H. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009, 94:2537-2543.
20. Mbikay M., Sirois F., Mayne J., et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett 2010, 584:701-706.
21. Tenenbaum A., Motro M., Fisman E.Z., Tanne D., Boyko V., Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005, 165:1154-1160.
22. Goldenberg I., Boyko V., Tennenbaum A., Tanne D., Behar S., Guetta V. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial. Arch Intern Med 2009, 169:508-514.
23. Scott R., O'Brien R., Fulcher G., et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009, 32:493-498.
24. Lambert G., Ancellin N., Charlton F., et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem 2008, 54:1038-1045.
25. Chan D.C., Hamilton S.J., Rye K.A., et al. Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients. Diabetes Obes Metab 2010, 12:752-756.
26. Welder G., Zineh I., Pacanowski M.A., Troutt J.S., Cao G., Konrad R.J. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 2010, 51:2714-2721.
27. Castro Cabezas M., de Bruin T.W., de Valk H.W., Shoulders C.C., Jansen H., Willem Erkelens D. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest 1993, 92:160-168.
28. De Man F.H., Cabezas M.C., Van Barlingen H.H., Erkelens D.W., de Bruin T.W. Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: post-prandial metabolism and relation to premature atherosclerosis. Eur J Clin Invest 1996, 26:89-108.
29. Ginsberg H.N. Insulin resistance and cardiovascular disease. J Clin Invest 2000, 106:453-458.
30. Rashid S., Watanabe T., Sakaue T., Lewis G.F. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 2003, 36:421-429.
31. Nagasawa T., Inada Y., Nakano S., et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 2006, 536:182-191.
32. Goa K.L., Barradell L.B., Plosker G.L. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia. Drugs 1996, 52:725-753.
33. Tenenbaum A., Motro M., Fisman E.Z. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 2005, 4:14.
34. Eisenberg S., Gavish D., Oschry Y., Fainaru M., Deckelbaum R.J. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment. J Clin Invest 1984, 74:470-482.
35. Keating G.M., Croom K.F. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 2007, 67:121-153.
36. Lee C.H., Olson P., Evans R.M. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003, 144:2201-2207.
37. Ogawa S., Takeuchi K., Sugimura K., et al. Bezafibrate reduces blood glucose in type 2 diabetes mellitus. Metabolism 2000, 49:331-334.
38. Tenenbaum A., Motro M., Fisman E.Z., et al. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004, 109:2197-2202.
39. Tenenbaum A., Motro M., Fisman E.Z., et al. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J 2005, 26:2032-2038.
40. Tenenbaum H., Behar S., Boyko V., et al. Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes. Atherosclerosis 2007, 194:265-271.
41. Damci T., Tatliagac S., Osar Z., Ilkova H. Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia. Eur J Intern Med 2003, 14:357-360.
42. Tan C.E., Chew L.S., Tai E.S., et al. Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control. Atherosclerosis 2001, 154:469-474.
43. Asano A., Kobayashi J., Murase Y., et al. Effects of fenofibrate therapy on plasma ubiquinol-10 and ubiquinone-10 levels in Japanese patients with hyperlipidemia and type 2 diabetes mellitus. Pharmacotherapy 2006, 26:447-451.
44. Flory J.H., Ellenberg S., Szapary P.O., Strom B.L., Hennessy S. Antidiabetic action of bezafibrate in a large observational database. Diabetes Care 2009, 32:547-551.
45. Costet P., Cariou B., Lambert G., et al. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem 2006, 281:6211-6218.
46. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005, 45:1649-1653.
47. Koh K.K., Han S.H., Quon M.J., Yeal Ahn J., Shin E.K. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005, 28:1419-1424.
48. Hiuge A., Tenenbaum A., Maeda N., et al. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol 2007, 27:635-641.
49. Mori Y., Oana F., Matsuzawa A., Akahane S., Tajima N. Short-term effect of bezafibrate on the expression of adiponectin mRNA in the adipose tissues: a study in spontaneously type 2 diabetic rats with visceral obesity. Endocrine 2004, 25:247-251.
50. Kita R., Takamatsu S., Kimura T., Kokuryu H., Osaki Y., Tomono N. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J Gastroenterol 2006, 41:686-692.
51. Noguchi Y., Tatsuno I., Suyama K., et al. Effect of fenofibrate on uric acid metabolism in Japanese hyperlipidemic patients. J Atheroscler Thromb 2004, 11:335-340.
52. Endo K., Miyashita Y., Sasaki H., et al. Probucol and atorvastatin decrease urinary 8-hydroxy-2′-deoxyguanosine in patients with diabetes and hypercholesterolemia. J Atheroscler Thromb 2006, 13:68-75.